抗发炎治疗药物市场规模、份额和成长分析（按药物类别、适应症、应用、通路和地区划分）－2025-2032年产业预测

预计到 2023 年，全球抗发炎治疗市场规模将达到 1,024 亿美元，到 2024 年将达到 1,073.2 亿美元，到 2032 年将达到 1,561.5 亿美元，预测期（2025-2032 年）的复合年增长率为 4.8%。

受类风湿性关节炎、气喘和发炎性肠道疾病（IBD）等自体免疫疾病和慢性发炎性疾病盛行率上升的推动，全球抗发炎治疗市场正经历显着成长。医疗系统持续面临的压力凸显了创新治疗方法的必要性。生物製药和标靶治疗已显着改善患者预后，而生物相似药的推出则加剧了市场竞争并降低了成本，从而扩大了先进疗法的可及性。随着人口老化导致慢性发炎患者数量不断增加，预计对这些治疗方法的需求将进一步增长。此外，众多针对白血球白细胞介素路径的研究生物製药展现出良好的前景，为精准医疗的发展铺平了道路，并巩固了长期的市场潜力。

全球抗发炎治疗市场驱动因素

全球抗发炎治疗市场的发展主要受自体免疫疾病和慢性发炎性疾病（例如发炎性肠道疾病、干癣、气喘和类风湿性关节炎）日益普遍的推动。关节炎等疾病患者数量的显着增长，推动了对先进治疗方案的需求。不断扩大的患者群体凸显了有效治疗方法的必要性，并促进了生物製剂和生物相似药在全球范围内的应用和普及。随着人们对这些复杂疾病的认识不断提高，市场正积极响应，推出创新解决方案，以满足寻求缓解持续性发炎症状的患者的多样化需求。

限制全球抗发炎治疗市场发展的因素

生物製药的高昂价格是患者获得治疗的一大障碍，尤其是中低收入国家。像阿达木单抗（Humira）这样的生物製药，每位患者每年的费用可能高达7.2万美元，这对许多患者来说难以负担。即使是通常被视为更具成本效益的替代疗法的生物相似药，也仍然面临着同样的经济挑战。此外，保险覆盖范围的不平衡和冗长的报销流程加剧了这种情况，限制了世界各地患者获得所需治疗的机会。因此，这些经济和製度上的障碍正在阻碍全球抗发炎治疗的整体疗效。

全球抗发炎药物市场趋势

全球抗发炎治疗市场正经历着向靶向生物製药和先进小分子化合物开发方向的重大转变。 IL-23抑制剂、JAK抑制剂和FcRn标靶抗体等创新药物正在取代传统的广谱免疫抑制剂。这一趋势反映了治疗适应症的策略性扩张，从小众自体免疫疾病扩展到溃疡性大肠炎等更常见的疾病，从而在提高疗效的同时最大限度地减少副作用。随着重磅药物面临来自学名药和生物相似药日益激烈的竞争，这种多元化不仅增强了市场潜力，也促使企业提供更多专业化且具有商业性价值的治疗方案。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2024）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

抗发炎治疗药物市场规模（依药物类别划分）及复合年增长率（2025-2032 年）

• 市场概览
• 抗发炎生技药品
• 非类固醇消炎剂（NSAIDs）
• 皮质类固醇

抗发炎治疗药物市场规模（按适应症和复合年增长率划分）（2025-2032 年）

• 市场概览
• 关节炎
• 呼吸系统疾病
• 多发性硬化症
• 银屑病
• 发炎性肠道疾病

抗发炎治疗药物市场规模（依应用领域划分）及复合年增长率（2025-2032 年）

• 市场概览
• 自体免疫疾病
• 发炎性疾病
• 呼吸系统疾病

抗发炎治疗药物市场规模（依分销管道划分）及复合年增长率（2025-2032 年）

• 市场概览
• 医院药房
• 零售药房

抗发炎治疗药物市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2024 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2024 年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2022-2024年营收年比比较

主要企业简介

• AbbVie（USA）
• Johnson & Johnson（USA）
• Pfizer（USA）
• F. Hoffmann-La Roche（Switzerland）
• Novartis（Switzerland）
• Merck & Co., Inc.（USA）
• AstraZeneca（UK/Sweden）
• Bristol Myers Squibb（USA）
• Amgen（USA）
• Eli Lilly and Company（USA）
• Sanofi（France）
• GSK（GlaxoSmithKline）（UK）
• Bayer（Germany）
• Gilead Sciences（USA）
• Takeda Pharmaceutical Company（Japan）
• Teva Pharmaceutical Industries（Israel）
• Boehringer Ingelheim（Germany）
• Regeneron Pharmaceuticals（USA）
• Viatris（USA）
• UCB（Belgium）

结论与建议

Global Anti-Inflammatory Therapeutics Market size was valued at USD 102.4 billion in 2023 and is poised to grow from USD 107.32 billion in 2024 to USD 156.15 billion by 2032, growing at a CAGR of 4.8% during the forecast period (2025-2032).

The global market for anti-inflammatory therapeutics is experiencing significant growth driven by the rising prevalence of autoimmune and chronic inflammatory diseases like rheumatoid arthritis, asthma, and inflammatory bowel disease (IBD). The persistent burden on healthcare systems underscores the need for innovative treatment options. Biologics and targeted therapies have significantly enhanced patient outcomes, while the introduction of biosimilars promotes competition and decreases costs, making advanced treatments more accessible. As the aging population continues to experience chronic inflammation, demand for these therapies is expected to rise. Furthermore, numerous pipeline biologics targeting interleukin pathways indicate a promising future, paving the way for advancements in precision medicine and solidifying long-term market potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Anti-Inflammatory Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Anti-Inflammatory Therapeutics Market Segments Analysis

Global Anti-Inflammatory Therapeutics Market is segmented by Drug Class, Indication, Application, Distribution Channel and region. Based on Drug Class, the market is segmented into Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids. Based on Indication, the market is segmented into Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis and Inflammatory Bowel Disease. Based on Application, the market is segmented into Autoimmune, Inflammatory Diseases and Respiratory Diseases. Based on Distribution Channel, the market is segmented into Hospital Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Anti-Inflammatory Therapeutics Market

The Global Anti-Inflammatory Therapeutics market is driven by the increasing prevalence of autoimmune and chronic inflammatory diseases such as inflammatory bowel disease, psoriasis, asthma, and rheumatoid arthritis. The significant rise in the number of individuals affected by conditions like arthritis has led to heightened demand for advanced therapeutic options. This growing patient population underscores the necessity for effective treatments, fueling the acceptance and utilization of biologics and biosimilars on a global scale. As awareness of these complex conditions expands, the market responds with innovative solutions aimed at addressing the diverse needs of patients seeking relief from persistent inflammatory ailments.

Restraints in the Global Anti-Inflammatory Therapeutics Market

The high cost of biologic treatments presents a significant barrier to access for patients, particularly in low- and middle-income nations. Biologics like Humira can reach annual costs of up to USD 72,000 for a single patient, making them prohibitively expensive for many individuals. This affordability challenge persists even for biosimilars, which are often intended to be more cost-effective alternatives. Additionally, discrepancies in insurance coverage and protracted reimbursement processes exacerbate the situation, limiting patient access to necessary care across various global regions. Consequently, these financial and systemic hurdles hinder the overall effectiveness of anti-inflammatory therapeutics on a global scale.

Market Trends of the Global Anti-Inflammatory Therapeutics Market

The Global Anti-Inflammatory Therapeutics market is experiencing a significant shift towards the development of targeted biologics and sophisticated small molecules. Innovations such as IL-23 inhibitors, JAK inhibitors, and FcRn-targeting antibodies are increasingly replacing traditional broad-spectrum immunosuppressants. This trend reflects a strategic expansion of therapeutic applications, moving from niche autoimmune disorders to common conditions like ulcerative colitis, enhancing therapeutic efficacy while minimizing side effects. As blockbuster drugs face intensified competition from generics and biosimilars, this diversification not only elevates the market potential but also drives companies to deliver more specialized and commercially valuable treatment options.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Anti-Inflammatory Therapeutics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Anti-Inflammatory Biologics
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Corticosteroids

Global Anti-Inflammatory Therapeutics Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Arthritis
• Respiratory Diseases
• Multiple Sclerosis
• Psoriasis
• Inflammatory Bowel Disease

Global Anti-Inflammatory Therapeutics Market Size by Application & CAGR (2025-2032)

• Market Overview
• Autoimmune
• Inflammatory Diseases
• Respiratory Diseases

Global Anti-Inflammatory Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy

Global Anti-Inflammatory Therapeutics Market Size & CAGR (2025-2032)

• North America (Drug Class, Indication, Application, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Indication, Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Indication, Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Indication, Application, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Indication, Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK/Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK (GlaxoSmithKline) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations